Nephros (NEPH) Stock Price, News & Analysis

Company Overview

Nephros, Inc. is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems. Nephros’ Water Purification System (WPS) is engineered to meet stringent U.S. Army and World Health Organization guidelines for field use, delivering potable water from untreated sources. In parallel, the MembraPure™ brand serves pharmaceutical and biotech customers requiring laboratory-grade water for research and manufacturing.

Nephros holds FDA 510(k) clearance for its medical-grade hollow fiber filters, underpinning its role in critical patient care applications. The company distributes products directly to healthcare providers and partners with OEMs and authorized distributors to serve markets across North America and select international territories. Its technology has been adopted by hospitals seeking to safeguard dialysis water and by research institutions requiring ultrapure water for sensitive assays.

Founded in 2005 and headquartered in Kinnelon, New Jersey, Nephros operates under the leadership of President and Chief Executive Officer Hal S. Zarem. The company maintains a focus on product innovation through ongoing research and development efforts, pursuing commercial partnerships and clinical collaborations to expand its footprint in water purification and filtration solutions.

Key Stats

• Today's Range: $3.21 to $3.35
• 50-Day Range: $2.78 to $3.80
• 52-Week Range: $2.66 to $6.42
• Volume: 3,450 shs
• Average Volume: 18,568 shs
• Market Capitalization: $36.27 million
• P/E Ratio: 47.72
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Moderate Buy

Nephros Stock Analysis - MarketRank™

Nephros scored higher than 51% of companies evaluated by MarketBeat, and ranked 524th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nephros has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Nephros has a consensus price target of $6.00, representing about 79.6% upside from its current price of $3.34.

Amount of Analyst Coverage

Nephros has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nephros is 47.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nephros is 47.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.00.

Price to Book Value per Share Ratio

Nephros has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.25% of the float of Nephros has been sold short.

Short Interest Ratio / Days to Cover

Nephros has a short interest ratio ("days to cover") of 0.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nephros has recently increased by 19.37%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nephros does not currently pay a dividend.

Dividend Growth

Nephros does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Nephros has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Nephros this week, compared to 1 article on an average week.

Search Interest

1 people have searched for NEPH on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nephros insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.70% of the stock of Nephros is held by insiders.

Percentage Held by Institutions

41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/15/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NEPH
• CIK: 1196298
• Web: www.nephros.com
• Phone: (201) 343-5202
• Fax: 201-343-5207
• Employees: 30
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Nephros: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +79.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.07
• Trailing P/E Ratio: 47.72
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.19 million
• Net Margins: 4.06%
• Pretax Margin: 4.12%
• Return on Equity: 7.66%
• Return on Assets: 5.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.55
• Quick Ratio: 3.12

Sales & Book Value

• Annual Sales: $18.79 million
• Price / Sales: 1.93
• Cash Flow: $0.13 per share
• Price / Cash Flow: 26.63
• Book Value: $0.96 per share
• Price / Book: 3.48

Miscellaneous

• Outstanding Shares: 10,860,000
• Free Float: 10,130,000
• Market Cap: $36.27 million
• Optionable: Not Optionable
• Beta: 1.51